hereafter) (6988:Tokyo) today announced achievement of predefined milestone by Bristol Myers Squibb Company (“BMS”, hereafter) (NYSE: BMY), based on the exclusive license agreement of ND-L02-s0201 (BMS-986263) for advanced liver fibrosis signed with BMS in 2016. The company...
“Nitto”) (6988: Tokio) ha anunciado hoy el logro de un hito predefinido por Bristol Myers Squibb Company (en adelante, “BMS”) (NYSE: BMY), relacionado con el acuerdo de licencia exclusivo de ND-L02-s0201 (BMS-986263) para la fibrosis hepática avanzada firmado...